Display options
Cite
Stefani A, Olivola E, Liguori C, et al. Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. Front Aging Neurosci. 2015;7:67doi: 10.3389/fnagi.2015.00067.
Stefani, A., Olivola, E., Liguori, C., Hainsworth, A. H., Saviozzi, V., Angileri, G., D'Angelo, V., Galati, S., & Pierantozzi, M. (2015). Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. Frontiers in aging neuroscience, 767. https://doi.org/10.3389/fnagi.2015.00067
Stefani, Alessandro, et al. "Catecholamine-Based Treatment in AD Patients: Expectations and Delusions." Frontiers in aging neuroscience vol. 7 (2015): 67. doi: https://doi.org/10.3389/fnagi.2015.00067
Stefani A, Olivola E, Liguori C, Hainsworth AH, Saviozzi V, Angileri G, D'Angelo V, Galati S, Pierantozzi M. Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. Front Aging Neurosci. 2015 May 04;7:67. doi: 10.3389/fnagi.2015.00067. eCollection 2015. PMID: 25999852; PMCID: PMC4418272.
Copy Download .nbib Format: NLM
Share it on

Front Aging Neurosci. 2015 May 04;7:67. doi: 10.3389/fnagi.2015.00067. eCollection 2015.

Catecholamine-Based Treatment in AD Patients: Expectations and Delusions.

Frontiers in aging neuroscience

Alessandro Stefani, Enrica Olivola, Claudio Liguori, Atticus H Hainsworth, Valentina Saviozzi, Giacoma Angileri, Vincenza D'Angelo, Salvatore Galati, Mariangela Pierantozzi

Affiliations

  1. Department of System Medicine, Università di Roma Tor Vergata , Rome , Italy ; IRCCS Fondazione Santa Lucia , Rome , Italy.
  2. Department of System Medicine, Università di Roma Tor Vergata , Rome , Italy.
  3. Policlinico Tor Vergata, Neurofisiopatologia , Rome , Italy.
  4. St George's University of London , London , UK.
  5. Neurocenter Svizzera Italiana , Lugano , Switzerland.

PMID: 25999852 PMCID: PMC4418272 DOI: 10.3389/fnagi.2015.00067

Abstract

In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited. Here we examine the possibility that assessment of endogenous catecholamine levels in cerebrospinal fluid (CSF) may fuel new therapeutic strategies. In reviewing the available literature, we consider the effects of levodopa, monoamine oxidase inhibitors, and noradrenaline (NE) modulators, showing disparate results. We present a preliminary assessment of CSF concentrations of dopamine (DA) and NE, determined by HPLC, in a small dementia cohort of either Alzheimer's disease (AD) or frontotemporal dementia patients, compared to control subjects. Our data reveal detectable levels of DA, NE in CSF, though we found no significant alterations in the dementia population as a whole. AD patients exhibit a small impairment of the DA axis and a larger increase of NE concentration, likely to represent a compensatory mechanism. While waiting for preventive strategies, a pragmatic approach to AD may re-evaluate catecholamine modulation, possibly stratified to dementia subtypes, as part of the therapeutic armamentarium.

Keywords: Alzheimer’s disease; CSF; catecholamine; dopamine; monoaminooxidase inhibitors

References

  1. Eur J Neurosci. 2003 Jul;18(1):149-54 - PubMed
  2. Ann Pharmacother. 1996 Oct;30(10):1122-9 - PubMed
  3. Eur J Med Chem. 2013 Apr;62:745-53 - PubMed
  4. J Alzheimers Dis. 2014;38(4):719-40 - PubMed
  5. J Neurosci. 2006 Jan 11;26(2):467-78 - PubMed
  6. J Neural Transm (Vienna). 2008 Sep;115(9):1313-9 - PubMed
  7. J Neural Transm (Vienna). 2012 Jul;119(7):861-75 - PubMed
  8. Exp Neurol. 2000 Dec;166(2):458-64 - PubMed
  9. Clin Neuropharmacol. 2014 Jan-Feb;37(1):9-16 - PubMed
  10. Eur Neuropsychopharmacol. 1992 Mar;2(1):31-5 - PubMed
  11. J Neurol Sci. 2009 Aug 15;283(1-2):109-15 - PubMed
  12. Am J Psychiatry. 1993 Feb;150(2):321-3 - PubMed
  13. J Cereb Blood Flow Metab. 2012 Dec;32(12):2135-45 - PubMed
  14. J Neurochem. 1996 Mar;66(3):1113-7 - PubMed
  15. Neurobiol Aging. 2012 Aug;33(8):1651-63 - PubMed
  16. Psychopharmacology (Berl). 2013 Dec;230(3):345-52 - PubMed
  17. World Neurosurg. 2013 Sep-Oct;80(3-4):S28.e1-8 - PubMed
  18. Biochem Pharmacol. 2014 Apr 15;88(4):426-49 - PubMed
  19. J Neural Transm (Vienna). 2003 Apr;110(4):373-80 - PubMed
  20. J Intern Med. 2014 Mar;275(3):251-83 - PubMed
  21. Am J Geriatr Psychiatry. 2009 Sep;17(9):744-51 - PubMed
  22. Cochrane Database Syst Rev. 2003;(1):CD000442 - PubMed
  23. Am J Geriatr Psychiatry. 2010 Apr;18(4):371-4 - PubMed
  24. J Neurol Neurosurg Psychiatry. 2015 Jun;86(6):655-9 - PubMed
  25. Curr Alzheimer Res. 2010 Sep;7(6):506-16 - PubMed
  26. N Engl J Med. 1997 Apr 24;336(17):1216-22 - PubMed
  27. Am J Geriatr Psychiatry. 1998 Spring;6(2):145-54 - PubMed
  28. JAMA. 2014 Jan 1;311(1):33-44 - PubMed
  29. Mol Neurobiol. 2012 Aug;46(1):217-20 - PubMed
  30. J Nucl Med. 2013 Aug;54(8):1331-8 - PubMed
  31. J Neurol Sci. 2006 Dec 21;251(1-2):124-8 - PubMed
  32. Biomed Res Int. 2014;2014:785039 - PubMed
  33. Neurobiol Aging. 2010 Apr;31(4):614-24 - PubMed
  34. Int J Biol Macromol. 2014 Jun;67:418-25 - PubMed
  35. Neuropsychopharmacology. 2009 Sep;34(10):2323-8 - PubMed
  36. Lancet Neurol. 2014 Mar;13(3):319-29 - PubMed
  37. Expert Opin Investig Drugs. 2011 Sep;20(9):1243-61 - PubMed
  38. Ann Neurol. 2011 Feb;69(2):248-56 - PubMed
  39. Alzheimers Dement. 2014 May;10(3):381-92 - PubMed
  40. Neurobiol Aging. 2000 Mar-Apr;21(2):343-8 - PubMed
  41. Ann N Y Acad Sci. 2014 Apr;1313:17-34 - PubMed
  42. Alzheimers Dement. 2015 Sep;11(9):1123-4 - PubMed
  43. Arch Neurol. 2003 Mar;60(3):337-41 - PubMed
  44. Drugs Aging. 2012 Oct;29(10):793-806 - PubMed
  45. Am J Alzheimers Dis Other Demen. 2007 Feb-Mar;22(1):57-61 - PubMed
  46. J Alzheimers Dis. 2012;30(1):1-16 - PubMed
  47. J Clin Psychopharmacol. 2008 Jun;28(3):296-301 - PubMed
  48. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2137-43 - PubMed
  49. J Neural Transm (Vienna). 2013 Jun;120(6):893-902 - PubMed
  50. CNS Neurol Disord Drug Targets. 2014 Mar;13(2):290-8 - PubMed
  51. J Clin Psychiatry. 2012 Jun;73(6):796-801 - PubMed
  52. Front Pharmacol. 2013 Apr 16;4:47 - PubMed
  53. Brain Res. 2007 Feb 2;1131(1):187-96 - PubMed
  54. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):349-52 - PubMed
  55. J Alzheimers Dis. 2012;31(3):593-9 - PubMed
  56. World Neurosurg. 2013 Sep-Oct;80(3-4):S27.e35-43 - PubMed
  57. Curr Alzheimer Res. 2010 Mar;7(2):158-64 - PubMed
  58. Mov Disord. 2011 Aug 15;26(10):1851-8 - PubMed
  59. Lancet Neurol. 2007 Apr;6(4):305-13 - PubMed
  60. Curr Pharm Des. 2010;16(6):672-83 - PubMed
  61. Neurobiol Aging. 2013 Apr;34(4):1105-15 - PubMed
  62. Curr Psychiatry Rep. 2011 Jun;13(3):211-8 - PubMed
  63. Alzheimers Dement. 2013 Sep;9(5):602-8 - PubMed
  64. J Neurochem. 2013 Sep;126(5):591-603 - PubMed
  65. Arq Neuropsiquiatr. 2014 Mar;72(3):227-31 - PubMed
  66. Neuropharmacology. 2013 Jan;64:108-13 - PubMed
  67. Eur J Med Chem. 2014 Mar 21;75:21-30 - PubMed
  68. Brain Res Bull. 2011 Feb 1;84(2):111-7 - PubMed
  69. Neurobiol Aging. 2013 Jan;34(1):298-308 - PubMed
  70. CNS Neurosci Ther. 2010 Aug;16(4):235-45 - PubMed
  71. Biol Psychiatry. 1999 Sep 15;46(6):756-65 - PubMed
  72. Prog Clin Biol Res. 1989;317:353-65 - PubMed
  73. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:94-9 - PubMed
  74. CNS Neurosci Ther. 2013 Aug;19(8):549-55 - PubMed
  75. Nat Rev Neurol. 2013 Jul;9(7):371-81 - PubMed
  76. J Alzheimers Dis. 2013;33(2):535-43 - PubMed
  77. J Neurol Sci. 2005 Oct 15;237(1-2):83-8 - PubMed
  78. Neurology. 1998 Mar;50(3):660-8 - PubMed

Publication Types

Grant support